Your browser is no longer supported. Please, upgrade your browser.
Settings
AGIO [NASD]
Agios Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.50 Insider Own0.30% Shs Outstand61.07M Perf Week0.81%
Market Cap2.72B Forward P/E- EPS next Y-7.21 Insider Trans-36.15% Shs Float55.60M Perf Month7.90%
Income-370.30M PEG- EPS next Q-1.59 Inst Own- Short Float10.14% Perf Quarter-16.22%
Sales78.80M P/S34.54 EPS this Y30.80% Inst Trans0.19% Short Ratio7.68 Perf Half Y-4.27%
Book/sh28.20 P/B1.69 EPS next Y-127.70% ROA103.90% Target Price62.43 Perf Year40.30%
Cash/sh29.21 P/C1.63 EPS next 5Y40.00% ROE130.00% 52W Range32.47 - 62.15 Perf YTD9.67%
Dividend- P/FCF- EPS past 5Y-8.60% ROI- 52W High-23.55% Beta1.62
Dividend %- Quick Ratio- Sales past 5Y28.00% Gross Margin98.00% 52W Low46.35% ATR1.35
Employees562 Current Ratio28.10 Sales Q/Q- Oper. Margin- RSI (14)57.39 Volatility2.63% 2.79%
OptionableYes Debt/Eq0.00 EPS Q/Q-14.70% Profit Margin- Rel Volume0.37 Prev Close47.75
ShortableYes LT Debt/Eq0.00 EarningsJul 29 BMO Payout0.00% Avg Volume733.59K Price47.52
Recom2.50 SMA203.85% SMA501.25% SMA200-5.51% Volume271,387 Change-0.48%
Jul-30-21Downgrade Goldman Neutral → Sell $58 → $39
Jul-01-21Initiated Raymond James Mkt Perform
Jun-10-21Initiated H.C. Wainwright Buy $88
Mar-01-21Upgrade SVB Leerink Mkt Perform → Outperform $50
Mar-01-21Downgrade JP Morgan Overweight → Neutral $64 → $54
Feb-26-21Downgrade SVB Leerink Outperform → Mkt Perform
Oct-22-20Upgrade Barclays Equal Weight → Overweight $46
Mar-04-20Initiated Barclays Equal Weight $50
Nov-26-19Initiated Cantor Fitzgerald Overweight $64
Sep-23-19Upgrade Guggenheim Neutral → Buy $55
May-23-19Resumed Goldman Neutral $55
Feb-15-19Upgrade SVB Leerink Mkt Perform → Outperform $80
Sep-25-18Initiated Leerink Partners Mkt Perform
May-23-18Initiated Citigroup Buy $117
Apr-11-18Reiterated Credit Suisse Outperform $80 → $95
Feb-15-18Reiterated SunTrust Buy $80 → $101
Feb-15-18Reiterated Needham Buy $72 → $86
Sep-15-17Initiated RBC Capital Mkts Outperform $78
Aug-10-17Reiterated Needham Buy $54 → $72
Aug-08-17Reiterated SunTrust Buy $68 → $80
Sep-20-21 02:57PM  
Aug-30-21 07:00AM  
Aug-24-21 09:00AM  
Aug-18-21 10:05AM  
07:37AM  
Aug-17-21 04:01PM  
Jul-31-21 03:13AM  
Jul-30-21 12:10PM  
Jul-29-21 05:00PM  
08:25AM  
07:00AM  
Jul-22-21 03:03PM  
Jul-19-21 12:16PM  
Jul-15-21 07:00AM  
Jun-29-21 11:15AM  
Jun-28-21 07:00AM  
Jun-25-21 03:44PM  
Jun-23-21 01:11PM  
Jun-22-21 11:45AM  
07:00AM  
Jun-21-21 11:07AM  
07:00AM  
Jun-18-21 09:58AM  
Jun-11-21 03:00AM  
03:00AM  
May-12-21 10:00AM  
09:32AM  
May-02-21 03:08AM  
Apr-30-21 08:46AM  
Apr-29-21 06:30PM  
09:25AM  
07:00AM  
05:45AM  
Apr-22-21 12:33PM  
Apr-20-21 11:56AM  
Apr-15-21 07:00AM  
Apr-01-21 07:00AM  
Mar-27-21 11:31AM  
Mar-25-21 04:01PM  
Mar-18-21 07:00AM  
Mar-01-21 07:00AM  
Feb-27-21 01:04AM  
Feb-26-21 10:04AM  
09:21AM  
07:00AM  
Feb-25-21 07:00PM  
07:00AM  
06:15AM  
Feb-23-21 07:00AM  
Feb-11-21 07:00AM  
Feb-04-21 11:54PM  
Jan-27-21 07:35AM  
Jan-26-21 04:01PM  
Jan-17-21 10:00AM  
Jan-11-21 07:00AM  
Jan-05-21 07:00AM  
Dec-23-20 08:30AM  
Dec-22-20 10:22AM  
07:39AM  
Dec-21-20 04:25PM  
01:46PM  
11:44AM  
10:10AM  
09:30AM  
07:39AM  
07:00AM  
07:00AM  
Dec-20-20 05:16PM  
Dec-07-20 04:30PM  
Dec-05-20 11:31AM  
Dec-04-20 08:00AM  
Dec-02-20 10:55AM  
Dec-01-20 07:00AM  
Nov-30-20 07:00AM  
Nov-25-20 07:00AM  
Nov-20-20 10:14AM  
Nov-13-20 10:57AM  
Nov-12-20 04:30PM  
Nov-07-20 07:16AM  
Nov-06-20 11:20AM  
Nov-05-20 09:00PM  
08:23AM  
07:00AM  
06:15AM  
Nov-04-20 11:46AM  
Oct-30-20 06:29AM  
Oct-29-20 04:01PM  
12:35PM  
Oct-22-20 12:34PM  
07:00AM  
Oct-19-20 12:06PM  
Oct-16-20 04:01PM  
Oct-05-20 12:00PM  
Sep-21-20 07:00AM  
Sep-16-20 05:10PM  
Sep-08-20 04:01PM  
Sep-05-20 07:27AM  
Aug-31-20 06:35AM  
Aug-29-20 11:31AM  
Aug-27-20 07:00AM  
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alenson CarmanPrincipal Accounting OfficerJun 21Option Exercise51.511,77791,5331,777Jun 23 05:28 PM
Alenson CarmanPrincipal Accounting OfficerJun 21Sale61.611,777109,4810Jun 23 05:28 PM
Bowden ChristopherChief Medical OfficerJun 18Option Exercise49.9948,4932,423,99163,980Jun 22 04:44 PM
Bowden ChristopherChief Medical OfficerJun 18Sale60.1148,4932,914,85115,487Jun 22 04:44 PM
Bowden ChristopherChief Medical OfficerJun 17Option Exercise39.762,50299,48017,989Jun 21 04:18 PM
Bowden ChristopherChief Medical OfficerJun 17Sale60.022,502150,17015,487Jun 21 04:18 PM
Bowden ChristopherChief Medical OfficerJun 10Option Exercise39.7620,853829,11536,340Jun 11 05:00 PM
Bowden ChristopherChief Medical OfficerJun 10Sale60.0620,8531,252,43715,487Jun 11 05:00 PM
Bowden ChristopherChief Medical OfficerJun 09Option Exercise39.767,149284,24422,636Jun 11 05:00 PM
Bowden ChristopherChief Medical OfficerJun 09Sale60.167,149430,11715,487Jun 11 05:00 PM
Bowden ChristopherChief Medical OfficerJun 08Option Exercise39.766,675265,39822,162Jun 09 04:06 PM
Bowden ChristopherChief Medical OfficerJun 08Sale60.076,675400,93915,487Jun 09 04:06 PM
Bowden ChristopherChief Medical OfficerJun 07Option Exercise39.764,268169,69619,755Jun 09 04:06 PM
Bowden ChristopherChief Medical OfficerJun 07Sale60.044,268256,23215,487Jun 09 04:06 PM
MARAGANORE JOHNDirectorMay 28Option Exercise0.001,686028,443Jun 02 04:09 PM
CLARK IAN TDirectorMay 28Option Exercise0.001,68604,964Jun 02 04:09 PM
Schenkein David PDirectorMay 28Option Exercise0.001,6860114,277Jun 02 04:07 PM
Clancy Paul JDirectorMay 28Option Exercise0.001,68604,964Jun 02 04:07 PM
Foster-Cheek Kaye IDirectorMay 28Option Exercise0.001,68607,164Jun 02 04:08 PM
Scadden DavidDirectorMay 28Option Exercise0.001,68605,535Jun 02 04:07 PM
Ho MaykinDirectorMay 28Option Exercise0.001,68604,964Jun 02 04:06 PM
Miles DarrinChief Commercial OfficerMay 14Sale55.413,462191,8297,209May 18 04:11 PM
Alenson CarmanPrincipal Accounting OfficerApr 16Sale55.891,11862,4850Apr 20 04:10 PM
Alenson CarmanPrincipal Accounting OfficerApr 15Sale54.0099153,5141,118Apr 16 04:33 PM
Miles DarrinChief Commercial OfficerMar 05Sale48.5850024,29010,671Mar 16 04:14 PM
Miles DarrinChief Commercial OfficerMar 01Sale47.992,200105,57811,171Mar 16 04:14 PM
Miles DarrinChief Commercial OfficerFeb 22Option Exercise0.00725013,272Feb 24 04:14 PM
Schenkein David PDirectorFeb 22Option Exercise0.002,7740113,412Feb 24 04:12 PM
Bowden ChristopherChief Medical OfficerFeb 22Option Exercise0.003,334016,396Feb 24 04:11 PM
Alenson CarmanPrincipal Accounting OfficerFeb 22Option Exercise0.0069201,994Feb 24 04:12 PM
Schenkein David PDirectorFeb 16Option Exercise0.008,1250113,178Feb 17 04:12 PM
Alenson CarmanPrincipal Accounting OfficerFeb 16Option Exercise0.0079001,863Feb 17 04:13 PM
Miles DarrinChief Commercial OfficerFeb 16Option Exercise0.00922015,463Feb 17 04:14 PM
Bowden ChristopherChief Medical OfficerFeb 16Option Exercise0.002,750015,131Feb 17 04:14 PM
Bowden ChristopherChief Medical OfficerFeb 14Option Exercise0.004,000012,381Feb 17 04:14 PM
Miles DarrinChief Commercial OfficerFeb 14Option Exercise0.008,666014,541Feb 17 04:14 PM
Alenson CarmanPrincipal Accounting OfficerFeb 14Option Exercise0.0088901,073Feb 17 04:13 PM
FOUSE JACQUALYN AChief Executive OfficerFeb 14Option Exercise0.0011,333061,761Feb 17 04:13 PM
Car BruceChief Scientific OfficerJan 06Option Exercise0.003,43708,284Apr 15 04:46 PM
Biller JonathanChief Financial OfficerDec 03Option Exercise0.005,753011,747Dec 07 06:21 PM